Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD)
Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD); Prospective, Double Blind, Randomized Placebo-control, Multi-center Study
Sponsor: Barzilai Medical Center
A PHASE2 clinical study on Bronchopulmonary Dysplasia, this trial is ongoing. The trial is conducted by Barzilai Medical Center and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barzilai Medical Center
- Bnai Zion Medical Center
- HaEmek Medical Center, Israel
- Kaplan Medical Center
- Laniado Hospital
- Meir Hospital, Kfar Saba, Israel
- Schneider Children's Medical Center, Israel
- Tel-Aviv Sourasky Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .